Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 5/20 | 0.56 |
| ▸ | INSR | P06213 | 3/20 | 0.56 |
| ▸ | IGF1R | P08069 | 3/20 | 0.56 |
| ▸ | ZAP70 | P43403 | 10/20 | 0.55 |
| ▸ | EGFR | P00533 | 4/20 | 0.51 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.46 |
| ▸ | ULK1 | O75385 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12729024 | 0.92 | ALK (0.66) | ALKINSRIGF1RZAP70EGFR | |
| SCHEMBL12729035 | 0.92 | ALK (0.66) | ALKINSRIGF1RZAP70EGFR | |
| SCHEMBL1912059 | 0.92 | ALK (0.66) | ALKINSRIGF1RZAP70EGFR | |
| SCHEMBL12780260 | 0.91 | ZAP70 (0.58) | ALKINSRIGF1RZAP70EGFR | |
| SCHEMBL12780084 | 0.86 | ZAP70 (0.72) | ALKINSRIGF1RZAP70EGFR | |
| SCHEMBL12780577 | 0.84 | ZAP70 (0.64) | ALKINSRIGF1RZAP70EGFR | |
| SCHEMBL12729034 | 0.83 | ZAP70 (0.69) | ALKINSRIGF1RZAP70EGFR | |
| SCHEMBL14175086 | 0.83 | ALK (0.67) | ALKINSRIGF1RZAP70EGFR | |
| SCHEMBL12892824 | 0.83 | ALK (0.66) | ALKINSRIGF1RZAP70EGFR | |
| SCHEMBL12917645 | 0.81 | ALK (0.52) | ALKINSRIGF1RZAP70EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | TYMS, TYMP, DPYD | ALK 3384/4885INSR 3201/4885IGF1R 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.